Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors

PURPOSE: We report the dose-escalation part of a phase I study of liposomal eribulin (E7389-LF) in Japanese patients with advanced solid tumors and no alternative standard therapy. PATIENTS AND METHODS: Patients ≥20 years old were enrolled. E7389-LF doses of 1.0 to 1.5 mg/m(2) once every two weeks (...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Jun, Shimizu, Toshio, Koyama, Takafumi, Iwasa, Satoru, Shimomura, Akihiko, Kondo, Shunsuke, Kitano, Shigehisa, Yonemori, Kan, Fujiwara, Yutaka, Tamura, Kenji, Suzuki, Takuya, Takase, Takao, Nagai, Reiko, Yamaguchi, Kohei, Semba, Taro, Zhao, Zi-Ming, Ren, Min, Yamamoto, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365350/
https://www.ncbi.nlm.nih.gov/pubmed/35180771
http://dx.doi.org/10.1158/1078-0432.CCR-21-3518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365350/
https://www.ncbi.nlm.nih.gov/pubmed/35180771
http://dx.doi.org/10.1158/1078-0432.CCR-21-3518

Ejemplares similares